This site is intended for healthcare professionals
Drug news

EU CHMP recommends refusal of application for Adlumiz (anamorelin) for anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer -Helsinn Birex Pharmaceuticals

Read time: 1 mins
Last updated:27th Jun 2017
Published:21st May 2017
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest